 Assistant Scientist
Assistant Professor of Ophthalmology, Harvard Medical School
Assistant in Ophthalmology, Massachusetts Eye & Ear
Clinical Associate, Massachusetts General Hospital
Dr. Ula Jurkunas received her M.D. degree Cum Laude from the University of Louisville in 2000 where she was a member of Alpha Omega Alpha Medical Honor Society. She is an Assistant Professor at Harvard Medical School and an Assistant Scientist at the Schepens.
Dr. Jurkunas is a clinician-scientist who performs corneal and refractive surgery at the Massachusetts Eye and Ear Infirmary and basic science research at the Schepens Eye Research Institute. Her main research focus is on the pathogenesis of Fuchs endothelial corneal dystrophy with emphasis on the role of oxidative stress in endothelial cell death seen in FECD. Specifically, her goal is to determine how oxidative stress causes molecular and cellular damage in the susceptible FECD endothelium. Dr. Jurkunas' studies are significant because understanding the key regulators of antioxidant defense and oxidative stress-induced cellular damage may facilitate development of pharmacotherapeutic treatment for FECD patients. As a recipient of the Harvard-Vision Clinical Scientist Development Program K12 Award , she laid the groundwork for the proposed research by developing experimental systems to test the proposed hypotheses.
Dr. Jurkunas' work has led to numerous peer-reviewed publications, review articles, and presentations nationally and internationally.
Contact Information
617-573-4300
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Education
2000, M.D., Cum Laude, University of Louisville
University of Louisville, Louisville, KY
2001 - 2004, Resident, Boston University, Boston, MA
2004 -2006, Fellow, Mass. Eye and Ear Infirmary, Harvard Medical School, Boston, MA
2006, Harvard School of Public Health, Boston, MA
2006, Fellow, Kyoto Prefectural University of Medicine
Research Projects
Fuchs Endothelial Corneal Dystrophy Genetics Study, Multi- center Clinical Trial
Pathophysiology of Fuchs’ Endothelial Corneal Dystrophy
“Effectiveness and Safety of Topical Bevacizumab
(Avastin) for Treatment of Corneal Neovascularization
|
